Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unresectable Non-small Cell Lung Cancer × endostar protein × Thoracic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 18 Lung Neoplasms 7 Unresectable Non-small Cell Lung Cancer 1 Small Cell Lung Carcinoma 1 Radiation Injuries 1 Pleural Effusion, Malignant 1 Adenocarcinoma of Lung 1

Interventions

endostar protein 1 Surgical Procedures, Operative 1 Endostatins 1 Drug Therapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06617936 2025-07-15

Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer.

Shandong Public Health Clinical Center

Phase 2 Recruiting

Unresectable Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡